SCHEMBL3143892

SCHEMBL3143892

CCc1cc(O)ccc1C1CCCCC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NUDT1 P36639 1/20 0.40
BACE1 P56817 1/20 0.40
HSP90AA1 P07900 1/20 0.40
ESR1 P03372 1/20 0.39
ESR2 Q92731 1/20 0.39
SIGMAR1 Q99720 3/20 0.38
DRD4 P21917 2/20 0.38
DRD3 P35462 2/20 0.38
PTGDR2 Q9Y5Y4 2/20 0.38
NFKB1 P19838 1/20 0.38
PRCP P42785 1/20 0.38
EBP Q15125 1/20 0.38
DRD2 P14416 1/20 0.38
JAK2 O60674 1/20 0.37
JAK1 P23458 1/20 0.37
JAK3 P52333 1/20 0.37
HDAC4 P56524 1/20 0.37
HDAC2 Q92769 1/20 0.37
HDAC8 Q9BY41 1/20 0.37
CEL P19835 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3809683 0.83 ESR2 (0.51) ESR1ESR2
SCHEMBL28134205 0.83 SLC6A2 (0.43)
SCHEMBL3655662 0.79 ESR1 (0.44) ESR1ESR2DRD4DRD3DRD2
SCHEMBL1398501 0.79 KMO (0.54) PTGDR2POLB
SCHEMBL17395670 0.79 MGLL (0.40) DRD4DRD3DRD2
SCHEMBL17699117 0.77 CHRNB2 (0.55) NUDT1BACE1HSP90AA1ESR1ESR2
SCHEMBL11702604 0.77 NUDT1 (0.44) NUDT1BACE1HSP90AA1PTGDR2JAK2
SCHEMBL3138891 0.77 PTGDR2 (0.53) SIGMAR1PTGDR2DRD2
SCHEMBL10870903 0.77 CNR1 (0.43)
SCHEMBL3143517 0.77 OPRL1 (0.40) NUDT1BACE1HSP90AA1ESR1ESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2137193-B1 SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF SANOFI SA (FR) 2017-08-09 EP disclosed
CN-104447792-A Substituted dihydro and tetrahydro oxazolopyrimidinones, preparation and use thereof SANOFI AVENTIS 2015-03-25 CN disclosed
US-8642603-B2 Substituted dihydro and tetrahydro oxazolopyrimidinones, preparation and use thereof SANOFI (FR) 2014-02-04 US disclosed
US-20100075994-A1 SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF SANOFI-AVENTIS (FR) 2010-03-25 US disclosed
CN-101675060-A Substituted dihydro and tetrahydro oxazolopyrimidinones, their preparation and use SANOFI AVENTIS 2010-03-17 CN disclosed
EP-2137193-A2 SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF Sanofi-Aventis (FR) 2009-12-30 EP disclosed
WO-2008112483-A2 SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF SANOFI-AVENTIS (FR) 2008-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100075994-A1 SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF GRM2, GRM1, GRIN2C NUDT1 1278/4885BACE1 1313/4885HSP90AA1 4686/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.